New hope for controlling debilitating nosebleeds in rare disease
Symptom relief
Recruiting now
This study is testing whether a drug called nintedanib can reduce the frequency and severity of nosebleeds in people with hereditary hemorrhagic telangiectasia (HHT), a rare genetic disorder. About 48 adult participants with moderate to severe nosebleeds will be randomly assigned…
Phase: PHASE2 • Sponsor: Dr. Romain Lazor • Aim: Symptom relief
Last updated Mar 30, 2026 14:30 UTC